|

Gocatamig Clinical Trials

2 actively recruiting trials across 1 location

Also known as: DS-3280, HPN328, MK-6070

Pipeline

Phase 1/2: 2

Top Sponsors

  • Merck Sharp & Dohme LLC2

Indications

  • Lung Cancer2
  • Cancer2
  • Small Cell Lung Cancer Extensive Stage1
  • Small Cell Lung Cancer1

Other1 trial

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Phase 1/2

Aurora, Colorado1 trial

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

University of Colorado Anschutz Medical Campus ( Site 1110)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.